From SNPedia
| Genotype | Effect |
|---|
| rs1799853(C;C) | normal; no change in warfarin metabolism |
| rs1799853(C;T) | CYP2C9*2 carrier; average 20% reduction in warfarin metabolism |
| rs1799853(T;T) | CYP2C9*2 homozygote; average 40% reduction in warfarin metabolism |
is a SNP in the
CYP2C9 gene. The
rs1799853(T) allele encodes a variant amino acid, cysteine, which has been linked to poor metabolism of
warfarin and thus sensitivity [
PMID 15608560]. The common nomenclature for this polymorphism is CYP2C9*2 (Cys amino acid, T allele; the SNP is also known as C430T or Cys144Arg).
The effect of CYP2C9 variants on drug metabolism should not be predicted without also considering CYP2C9*3, defined as the common loss of function variant rs1057910(C) [1] (NM_000771:c.430C>T, NP_000762:p.144R>C) [PMID 8004131] [2].
Individuals carrying this SNP may show increased risk of developing acute gastrointestinal bleeding during the use of NSAIDs that are CYP2C8 or CYP2C9 substrates, such as aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.[PMID 19422321]
| ? | (T;T) (C;C) (C;T) |
|---|
 |
| GWAS snp
|
| PMID
| [PMID 19300499]
|
| Trait
| Warfarin maintenance dose
|
| Title
| A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
|
| Risk Allele
|
|
| P-val
| 1E-31
|
| Odds Ratio
| 0.54 [0.45-0.63] mg/week decrease
|
